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Kenyaa b s t r a c t
Prompt provision of post-exposure-prophylaxis (PEP) including vaccines and rabies immunoglobulin
(RIG) to persons bitten by suspect rabid dogs is a key strategy to eliminating human deaths from dog-
mediated rabies in Kenya by 2030. We assessed the availability, forecasting and supply chain logistics
for rabies PEP in Kenya, compared with the system used for vaccines in the expanded program of immu-
nization (routine vaccines). Semi-structured questionnaires capturing data on forecasting, procurement,
distribution, cold chain and storage, monitoring and reporting for routine vaccines and rabies vaccines
and RIG were administered to 35 key personnel at the national, county, sub-county and health facility
levels in five counties. Results showed large variability in PEP availability (stockouts ranged from 3 to
36 weeks per year) with counties implementing rabies elimination activities having shorter stockouts.
PEP is administered intramuscularly using the 5-dose Essen regimen (day 0, 3, 7, 14 and 28). PEP costs
to bite patients were reported to range from 10 to 15 US dollars per dose; RIG was seldom available. A
less robust supply and logistics infrastructure is used for rabies PEP compared to routine vaccines.
Forecasting and monitoring mechanisms for rabies PEP was poor in the study counties. The supply of vac-
cines from the national to the sub-national level is mainly through two government agencies and a pri-
vate agency. Since government decentralization, the National Vaccine and Immunization Program has
remained as the main supplier of the routine vaccines, playing a lesser role in the supply of rabies bio-
logicals. Adoption of the dose-saving intradermal route for PEP administration, reduction of PEP costs
to patients, and placing rabies vaccines within the routine vaccines supply and logistics system would
significantly improve PEP availability and accessibility to persons at risk of rabies; a critical step to
achieving elimination of human deaths from rabies.
 2019 Published by Elsevier Ltd. This is an open access article under the CC BY IGO license. (http://crea-
tivecommons.org/licenses/by/3.0/igo/).1. Introduction
The global target for the elimination of dog-mediated human
rabies supported by the World Health Organization and partners
has been set for 2030 [1]. The feasibility of this goal, including in
Africa and Asia where most of the estimated 59,000 annual human
rabies deaths occur, is supported by the existence of potentbiologicals for humans and animals, and relatively well understood
epidemiology of the disease with domestic dogs the primary reser-
voir of the virus and source of human infections [2–6].
The strategies for achieving zero human deaths from dog rabies
are hinged on two complementary interventions. The first is inter-
rupting transmission between domestic dogs thereby reducing
dog-to-human transmission. Control and elimination of dog rabies
through mass dog vaccinations has been successful in different set-
tings previously endemic for rabies [7–9]. The second intervention
is directly reducing the risk for human rabies, through
pre-exposure vaccination for high-risk groups and prompt
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administration of rabies vaccines, and where indicated, infiltration
of rabies immunoglobulin (RIG) into and around the wound(s)
[10,11].
Rabies vaccines have been improved over the last few decades,
from nerve tissue vaccines that could induce severe adverse reac-
tions to the safer and highly immunogenic cell culture vaccines
mostly in use today [11,12]. However, prompt provision of PEP
remains a challenge in settings with high incidence of dog bites
and dog rabies, leading to unnecessary and preventable human
deaths. This has been attributed to the failure of health care systems
in rabies endemic regions to ensure steady availability of PEP for bite
patients that seek care; socio-economic challenges where bite
patients cannot afford the cost of PEP or suffer delays in receiving
PEP owing to long distances they have to cover to access health care,
or poor health care seeking by bite patients due to a lack of knowl-
edge about the risk of rabies and its prevention [13–15].
In Kenya, rabies is endemic and has been reported in the country
for more than a hundred years [16]. In 2014, Kenya launched a 15-
year strategy to end human deaths from dog rabies by 2030. The
strategy uses a progressive reduction in rabies risk, starting elimina-
tion programs in five pilot counties (Siaya, Kisumu, Makueni, Kitui,
Machakos) before extending to neighbouring counties until the
country is free of rabies [16,17]. The elimination program is focused
on mass dog vaccinations, prompt provision of PEP, public health
education and awareness on rabies, strengthening rabies surveil-
lance, and operational research to aid in optimal delivery of these
interventions. In 2010, Kenya adopted a new constitution thatFig. 1. Map of Kenya showing the study counties comprising pilot counties where rabies
pilot counties (Nairobi, Marsabit and Kwale Counties in orange). (For interpretation of the
this article.)changed governance from a central government system to a
devolved system consisting of two levels of government: national
government and 47 county governments. As a result, in 2012 health
services were devolved to be financed and run by the county govern-
ments. Although rabies elimination activities have commenced in
parts of the country, there is little data on PEP and RIG availability
and accessibility in counties and nationally.
This study addresses the strategy of prompt provision of PEP for
patients bitten by suspect rabid dogs. We assessed the rabies vac-
cine infrastructure including the logistics flow, demand, and sup-
ply and forecasting for PEP and RIG at the national, county and
sub-county levels. We compared it with the system used for rou-
tine vaccines to identify the challenges and opportunities for
improving the availability, accessibility, and affordability of rabies
PEP to achieve elimination of human rabies in the country.
2. Methods
This survey was conducted in five of 47 counties in Kenya
between May and June 2017. To establish the country’s situation
in regards to PEP, data over 5 years prior to the interview date were
collected. The selection of the study counties was purposive to
allow for representation of regions that had started systematic
rabies elimination activities (Makueni and Siaya Counties) such
as mass dog vaccinations and public health campaigns and for
those yet to commence activities (Nairobi, Kwale and Marsabit
Counties) (Fig. 1). Nairobi County was included in the study to rep-
resent an urban population and to allow for interviews with theelimination activities were ongoing (Makueni and Siaya Counties in green) and non-
references to colour in this figure legend, the reader is referred to the web version of
Table 1
Details of the eight thematic areas covered in the rabies biologicals survey and the
data collected.
Thematic areas Variables
Program delivery - Availability and changes in PEP demand, supply and
logistics of delivery
- Cost of PEP to health facilities and bite patients
- Information sharing to bite patients on PEP availabil-
ity, and facilities
Procurement - Differences between procurement for routine and
non-routine vaccines
- Organization of the procurement system and PEP
types procured
- Costs and time taken from procurement to delivery
- Frequency of procurement and individuals
responsible
Request - Requesting procedure for PEP at sub-county, county
and national levels compared to routine vaccines
- Frequency of requests, individuals responsible
Distribution - Distribution procedures for PEP from national to
county to sub-county levels comparison with routine
vaccines
- Frequency and individuals responsible
Cold chain and
storage
- Cold chain and storage facilities for PEP, compared to
routine vaccines national to county to sub-county
levels
Forecasting - Methods of quantification and forecasting for PEP
- Comparison with routine vaccines
- Individuals responsible
Monitoring and
utilization
- System for monitoring usage and stocks of PEP
- Comparison with routine vaccines
- Individuals responsible
- PEP stock out periods and wastages
- Monitoring of patients to ensure compliance with
completion of PEP
Reporting - Data collection and reporting on PEP use
- Reporting of adverse effects and PEP wastage
- Individuals responsible and frequency of reporting
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cine and Immunization program (NVIP), the Kenya Medical Sup-
plies Agency (KEMSA), and the Mission for Essential Drugs and
Supplies (MEDS). NVIP is responsible for all the routine vaccines
used in the Expanded Program for Immunization (EPI), whereas
KEMSA and MEDs mainly support medical supplies including
non-routine vaccines for public and private health facilities
respectively.
The survey focused on eight thematic areas related to rabies PEP
and RIG at the national, county and sub-county levels: program
delivery, procurement, requesting, distribution, cold chain and
storage, forecasting, monitoring and utilization, and reporting.
The details of the information collected under each of the thematic
areas are provided in Table 1. The survey questions used were
adopted from the PEP logistics and flow questionnaire developed
by the World Health Organization and US Centers for Disease Con-Table 2
Details of the persons, their designation, institutions, and health facilities that participate
Level Institution
National level National Vaccine Immunization Program (NVIP)
Mission for Essential Drugs and Supplies (MEDS)
Kenya Medical Supplies Agency (KEMSA)
County level Marsabit, Nairobi, Makueni, Siaya, Kwale
Sub-county level Marsabit (Saku sub-county)
Nairobi (Kasarani sub-county)
Makueni (Kibwezi West and Makueni sub-counties)
Siaya (Alego Usonga sub-county) Kwale (Lunga Lunga sub-cou
Health facility level Marsabit and Laisamis sub-county hospitals
Makindu and Makueni County Referral Hospital
Siaya County Referral Hospital, Lwak Mission Hospital),
Kwale (Msambweni County Referral Hospital)trol and Prevention, and implemented across several countries
(Appendix Supplementary Table 1).
Separate questionnaires were developed to gather information
from relevant persons at NVIP, KEMSA and MEDS at the national
level, and directors of health, routine vaccines logisticians, surveil-
lance officers, and pharmacists at the county and sub-county
levels. Table 2 provides details on the designation of the 35 persons
interviewed for this study, and the specific organizations and
health facilities that participated in the survey.
The questionnaires were programmed on the Commcare
phone-based application to allow both electronic capture of quan-
titative data, and voice recording of the interviews to capture qual-
itative data. The questionnaires were pre-tested and consent for
voice recording and participation in the study obtained from each
respondent. The voice records were transcribed by a pair of tran-
scribers allowing for crosschecking of the transcripts.
Ethical clearance for the study was obtained from the Kenya
Medical Research Institution Scientific and Ethics Review Unit
(KEMRI-SERU protocol No. 3268).
3. Results
A total of 35 interview surveys were completed with four
respondents drawn from KEMSA, NVIP and MEDS at the national
level, 23 respondents at the county and sub-county levels and 8
health care workers at the health facilities.
3.1. Overview of the vaccine supply chain structure in Kenya
The supply of routine and non-routine vaccines in Kenya is by
three main institutions: NVIP, KEMSA and MEDS. NVIP is the pri-
mary government institution responsible for sourcing and supply
of routine (EPI) vaccines used in both the public and private health
sector. In addition, NVIP supplies non-routine vaccines including
typhoid, cholera, and human papilloma virus vaccines. Human
rabies vaccines are treated as non-routine vaccines and are not
anchored on a specific national program.
KEMSA (a government organization) is the main supplier of
rabies vaccines for public health facilities and MEDS (a for-profit
private organization) supplies the private health sectors facilities
with the vaccines. KEMSA and MEDS receive orders for these vac-
cines from individual counties, and sometimes directly from health
facilities.
NVIP orders for the routine vaccines go through the United
Nations Children’s Fund (UNICEF) with facilitated cost estimation,
scheduling, procurement and delivery of quality vaccines. Purchase
of routine vaccines is financed through the Kenya Government and
Gavi, the Vaccine Alliance. NVIP reported procuring small quanti-
ties of rabies vaccines but this was rare and dependent on requests
received from counties and the availability of funds.d in the survey at National, County and sub-County level.
Designation
Manager supply chain, Quality Assurance Manager,
National depot manager, Regional depot manager, Program officer
County EPI Logistician, Pharmacist, Surveillance officer,
Public Health officer
nty)
Sub-county Public Health Officer, sub-county Disease Surveillance officer,
sub-county EPI Logistician, sub-county pharmacist
Pharmaceutical technologist
Medical officer in-charge
Facility clinical officer
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for storage of vaccines received before distribution to the counties.
At the lower level, NVIP maintains depots at regional and sub-
county levels while KEMSA maintains depots at regional level.
There are vaccine logisticians placed at health facilities, sub-
county and county levels specifically to support the supply and dis-
tribution of routine vaccines. At these lower levels, rabies PEP and
RIG are handled together with other medical supplies.
3.2. PEP and RIG delivery
Before the change from a centralized to a devolved government
system, NVIP was the main supplier of rabies vaccines and RIG.
This role changed after decentralization with NVIP remaining as
the main supplier of routine vaccines, and having a lesser role for
rabies biologicals. Our study showed NVIP last procured rabies vac-
cines in 2015 as an emergency request from counties. As a result,
the demand for rabies vaccines from KEMSA and MEDS and their
supply of PEP increased (MEDS reported an increase of over 250%
in the last five years), making the two bodies the primary suppliers
of rabies biologicals. At the County level, 3 of the 5 study counties
reported an increase in PEP availability related to increased control
of health budgets following devolution, but quantitative informa-
tion on these changes were not available.
For the 12 months preceding the PEP surveys, all counties
reported experiencing stockouts for the rabies vaccines. Availabil-
ity of rabies biologicals varied by counties. Counties implementing
elimination activities (Makueni and Siaya Counties) had shorter
stockouts (3.5 weeks and 5 weeks respectively), while Kwale, Nair-
obi and Marsabit Counties reported stockouts of 36, 32 and
8 weeks respectively. The main reason for stockouts reported
was the high cost of PEP, delayed procurement, coupled with a
high incidence of dog bites.
RIG was rarely provided, with NVIP and MEDS reporting to have
been out of stock for the preceding five years. KEMSA stocked RIG
previously but the counties did not order for it, leading to expiry of
available stock and losses for KEMSA. Information on the number
of vials, type and utilization of RIG was not available. It can how-
ever be assumed that use of RIG was negligible, as all respondents
at the sub-national level did not know about RIG. Information on
the category of bite, that would be important for RIG prioritization,
was not recorded.
Rabies PEP vaccine was administered through the intramuscu-
lar route in 5 doses (the ‘‘Essen” regimen - day 0, 3, 7, 14 and
28). None of the counties reported using the intradermal vaccina-
tion regimens recommended by WHO.
3.3. Rabies PEP forecasting, request and procurement processes
Rabies PEP forecasting is required at three main levels:
health facility where PEP is administered to bite patients,
sub-county/county level that funds procurement of vaccines and
distributes PEP to the health facilities, and at national level to guide
quantities ordered and imported into the country. The methods of
forecasting at the three levels are different, and there are further
differences in the forecasting for routine versus non-routine
vaccines.
At the national level, forecasting for routine vaccines uses a
combination of consumption data, estimated size of the target pop-
ulation, projected population growth and expected level of vaccine
wastage. Whereas this holds true for routine vaccines that do not
require counties to pay for the vaccines, the volumes of rabies vac-
cines ordered are dependent on estimation of the numbers that
counties will likely order and pay for.
To determine vendors that will supply the vaccines at the
national level, KEMSA uses an open tender system specifying quan-tities, desired quality and delivery timelines, and inviting local and
international vendors to place their bids. Submitted bids are eval-
uated based on both documentation and quality of pre-delivery
samples. MEDS uses a closed system consisting of annual evalua-
tion of existing and prospective suppliers by a technical commit-
tee, that may include visiting manufacturing sites.
The forecasting system for non-routine vaccines at county level
is less developed as compared to routine vaccines. Rabies procure-
ment at county level is based on consumption data and does not
take into account number of bites from suspect rabid dogs – data
routinely collected at health facilities through the Ministry of
Health District Health Information Systems (DHIS2), or data on
patients that did not access PEP at the time of seeking care.
Requests for routine vaccines are done using a standardized
vaccine request/order form filled in by sub-county logisticians,
aggregated at the county level and submitted to NVIP. Similar
online forms are filled at the county level to request for rabies vac-
cines from MEDS and KEMSA. However, the procurement of rabies
vaccines at the county level is irregular and dependent on the
county’s allocation of funds towards rabies. Three of the 5 study
counties cited financial constraints as the main reason for delays
in procuring PEP.
On average, PEP costed counties approximately 8USD per dose to
procure from KEMSA and MEDS. In the absence of government sub-
sidies for PEP, bite patients paid 10–15 USD per dose at the county
level. Costs of PEP to the patient were not standardized and differed
by county. In the 4 months preceding the survey, Siaya county
reported subsidizing PEP costs by 50% enabling bite patients to pay
5USD per dose. Makueni County provided PEP for free for any resi-
dent enrolled in the Universal Health Coverage (UHC) plan. RIG pro-
curement at the national level was erratic and KEMSA reported
procuring equine RIG at approximately 8USD per vial between
2014 and 2016. KEMSA had not procured any RIG in the 12months
preceding the survey interview, which was attributed to a lack of
demand for the product at the counties. The cost of RIG to patients
from the private sector was approximately USD70 per vial.
3.4. Vaccine distribution and supply duration
The distribution of routine vaccines from the national level to
the counties uses a push mechanism. Vaccines are shipped to the
locality of request. Whereas routine vaccines have storage depots
located at the county/sub-county headquarters, rabies vaccines
do not use these facilities resulting in logistical difficulties of get-
ting them to the health facilities.
Rabies vaccines are instead delivered to the county headquar-
ters, and supplied to the health facilities through a pull distribution
system organized around the monthly County Health Management
Team (CHMT) meetings. Sub-County health officials attending the
meetings collect the vaccines and deliver to the health facilities.
Four of five counties reported stocking rabies vaccines only up to
the sub-county level. Only Marsabit county reported stocking PEP
in some health facilities with reported high number of bite cases.
On average, once ordered, delivery of routine vaccines from inter-
national distributors took 6 weeks to get to NVIP, and 8 and
11 weeks to get to MEDS and KEMSA respectively. Supply from the
national to the subnational levels took 1 week for routine vaccines
and rabies vaccines supplied to private facilities via MEDS versus
4 weeks for supply of public health facilities via KEMSA (Fig. 2).
3.5. Availability of cold chain equipment
The non-routine vaccines and routine vaccines do not share
the cold chain facilities. Routine vaccines have specific fridges at
the sub-county level in more than 50% of the sub-counties in the
study counties. Counties reported not having specific fridges for
Fig. 2. Schematic diagram showing the vaccine distribution system in Kenya.
A32 G. Wambura et al. / Vaccine 37 (2019) A28–A34non-routine vaccines at the sub-county level. Only Makueni
reported having fridges for non-routine vaccines in six out of 40
health facilities.3.6. Monitoring and evaluation
Monitoring of routine vaccines by NVIP is elaborate and robust,
consisting of an electronic system capturing details of stock levels
up to the sub-county level, supported by regular field visits and
supervision on routine vaccines management at the county and
sub-county levels. KEMSA and MEDS have monthly and semi-
annual stock takes to monitor product movement. In contrast,
monitoring of rabies vaccines at the county level is manual and
the tools used are not standardized across countries (for routine
vaccines, respondents identified the same tool to monitor vaccine
usage within counties).
Although rabies PEP requires multiple doses, there was no sys-
tem in place to ensure dose completion compliance. Patients are
advised to complete all five doses and dates are detailed in the
patient’s card, however anti-rabies registers were not in use in
counties and no follow up is made to patients who do not complete
their doses. Data on anti-rabies vaccine wastage is not regularly
collected or reported. Adverse events from medicines and vaccines
are reported to the Pharmacy and Poisons Board through standard-
ized forms that include information on symptoms experienced,
date of symptom onset, and product batch numbers. Table 3 sum-
marizes the similarities and differences between routine and non-routine vaccines by the three main vaccine suppliers and the
counties.4. Discussion
This study has shown considerable in-country variability in the
availability of rabies vaccines and immunoglobulin, a less robust
and inadequate supply system for rabies biologicals operated sep-
arately to that used by routine vaccines, use of the intramuscular
route for PEP administration as opposed to the dose-saving intra-
dermal route, and a high cost of rabies PEP and RIG to bite patients.
Taken together, our results point to a sub-optimal system requiring
specific improvements to achieve prompt provision of rabies PEP
for persons exposed to rabies.
The large differences in the stockout periods between counties
indicate differential prioritization of rabies at the local level.
Awareness created in counties implementing rabies elimination
activities likely resulted in the increased availability of the vaccines
and relatively shorter stockout periods. For the country to achieve
the 2030 goal of elimination of human rabies, provision of readily
available and affordable PEP across all counties where rabies is
endemic, is important. A good example is Thailand which has dra-
matically reduced human deaths from rabies to below 10 cases per
year by educating the public and health care workers, and provid-
ing PEP free of charge across the country, before mass dog vaccina-
tions reached the recommended 70% coverage [18]. Ultimately,
elimination of human rabies is dependent on eliminating the
Table 3
Table detailing similarities and differences between routine and non-routine vaccines by each of the three main suppliers and at the counties.
MEDS KEMSA NVIP Counties
Procurement system Closed tender Open tender Closed tender Direct order
Main suppliers of
vaccines
Sanofi Pasteur Medisel Kenya Limited, Sai
pharmaceuticals Limited, Surgipharm
Limited
GAVI KEMSA, MEDS,
NVIP
Supply duration 8 – 12 weeks 10 – 12 weeks 6 weeks 1 – 4 weeks
Frequency of supply Quarterly/on demand Quarterly/on demand Quarterly/on demand Quarterly/on
demand
Institutions distributed
to
Counties, non-governmental,
community-based and faith-based
institutions
Counties, non-governmental
organizations, Faith-based institutions,
Public institutions
Counties Sub-counties and
health facilities
Distribution time 3 – 7 days Up to 1 month 3 – 7 days 1 day
Vaccines available Yellow Fever, Typhoid and Hepatitis
B, Rabies
Yellow Fever, Typhoid and Hepatitis B,
Rabies
Routine vaccines, Hepatitis B,
Yellow Fever, Meningitis,
Tetanus etc.
Routine and non-
routine vaccines
Brand of PEP Verorab Indirab Does not procure PEP Dependent on
supplier
Cost per dose to the
organization (rabies
vaccine)
Not revealed USD 3 – 12 Not applicable for rabies. Cost
varies for other types of vaccine
USD 8–12
Cost per dose to the
organization (RIG)
Does not supply RIG USD 7 – 9 Does not supply RIG Does not procure
RIG
Department/person
responsible
Procurement Procurement Procurement Pharmacist – PEP
Routine vaccine
logistician
Monitoring and
evaluation tools used
Electronic (enterprise resource)
system
Ledger books and stock management tools Ledger books and stock
management tools
Ledger books and
improvised
registers
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during the elimination phase is an effective and cost-effective
approach to progressively reducing human deaths from rabies [19].
To increase rabies vaccine availability at health facilities, the
current forecasting and stock monitoring requires improvements.
Several opportunities to improve the system exist including pro-
gram changes that would allow rabies vaccines to use the existing
more developed supply system used for routine vaccines. Rabies
vaccines are demand-driven and mainly required for a targeted
and relatively small group, and are therefore unlikely to overload
an existing system. Re-introduction of rabies vaccine into the
routine vaccine infrastructure as was the case before devolution
is therefore not expected to affect the provision of existing
vaccines. However, the impact of such a policy on how the system
should be monitored [20,21].
A limitation of our study was that we were unable to obtain
information from respondents on the number of bite victims
receiving vaccine or the number of vials purchased and used. This
was because there are no systems for monitoring these numbers
and highlights the need for improvement. The dog-bite data rou-
tinely collected at health facility level and transmitted through
the District Health Information System 2 (DHIS2) health surveil-
lance open resource tool was not utilized in forecasting for rabies
vaccines, although it has potential to be used in this way. Addition-
ally, the lack of a monitoring system for dose-completion at health
facilities can be improved through the DHIS2 system by including
individual-level data as opposed to the current aggregate data col-
lection. Such an improvement in DHIS2 reporting can improve
surveillance data for rabies and provide a basis for advocacy to
raise the priority of and funding for rabies vaccines [22].
The cost of PEP remains a major barrier to PEP accessibility. Sev-
eral opportunities to reduce the cost and increase accessibility
exist. The first is the adoption of the WHO recommended dose-
saving intradermal route for administration of PEP versus the
intramuscular route currently in use [11]. Intradermal injections
are not new and are routinely used for vaccination against tubercu-
losis, including in rural areas. Adoption of the ID route requiresadvocacy to overcome challenges of inertia to use of new methods
and off-label use of ID administration before the vaccine manufac-
turers have updated vial labels. Introduction of animal bite centers
could pool bite patients in a region, and integrated bite case man-
agement could aid in judicious and appropriate administration of
PEP, by confirming rabid dogs and identifying healthy dogs where
PEP is not required [23–25]. The second opportunity comes with
introduction of universal health coverage (UHC). In Makueni
County where UHC is being implemented, patients enrolled in
the program do not pay to receive PEP injections. To ensure avail-
ability of the vaccines in the context of UHC, proper forecasting and
supply systems coupled with adequate financing for the UHC
programs are required. Such systems for rabies could benefit from
systems developed for routine vaccines supported by Gavi, the
Vaccine Alliance. Gavi recently updated their vaccine investment
strategy and included rabies vaccines in their list of vaccines prior-
itized for future support. Gavi support could facilitate the shared
use of cold chain and vaccine supply infrastructure and critically
would make rabies vaccines available to bite patients at the point
of care at no cost.
5. Conclusion
Prompt provision of rabies PEP remains a critical strategy to
Kenya achieving zero human deaths from rabies by 2030. Integrat-
ing the provision of rabies vaccines and immunoglobulin within
the health system including using existing infrastructure for
routine vaccines, extending the DHIS2 reporting system to cover
PEP demand, use and compliance, supporting universal health
coverage, better health financing and free provision of PEP, as well
as adoption of ID vaccination regimens, and creation of integrated
bite management programs can all increase progress towards
eliminating human rabies by 2030.
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